Nasdaq · Healthcare
Bioventus Inc. (BVS)
As-reported financials and recent SEC filings for Bioventus Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$568.1M
Net income
$22.7M
Net margin
4.0%
Diluted EPS
$0.33
ROE
10.0%
P/E (TTM)
23.9×
Market cap
$662.6M
Debt / equity
1.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M |
| Gross profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M |
| Operating income | $54.0M | $-15.2M | $-81.7M | $-167.2M | $12.1M |
| Net income | $22.7M | $-36.1M | $-156.2M | $-158.7M | $19.4M |
| Diluted EPS | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →8-K2026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →Go deeper on BVS
Search Bioventus Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.